Nifty
Nifty Makes History After 12 Sessions Without Crossing Prior High

Lumic
15 days ago
Nifty Makes History After 12 Sessions Without Crossing Prior High
KEY POINTS
Nifty has failed to close above the previous day's high for 12 straight trading sessions
Repeated rejection at higher levels signal weak buying and limited upside in Nifty
A sustained move above key resistance is needed before the index can signal trend reversal
LUMIC INSIGHT
Wait for Nifty to break resistance before investing
This 'Insights' piece delves into Nifty's recent trading pattern, noting its inability to surpass the prior day's high for 12 consecutive sessions. This trend suggests subdued buying interest and limited upward momentum in the Indian stock market. Analysts observe repeated rejections at higher levels, indicating a need for a sustained breakout above key resistance points before a genuine trend reversal can be confirmed. Understanding Nifty's technical analysis and market momentum is crucial for navigating the current Indian stock market landscape. The Nifty 50's behaviour here points to caution, as highlighted by our Lumic take, advocating patience until a clear upward signal emerges.
More in Nifty

Lumic
3 days ago
Nifty
Closing Auction Session Cuts Derivatives Volume, Raising Liquidity concern
- August derivatives turnover hit multi-month lows on NSE and BSE after CAS changed trading
- NSE's August derivatives turnover fell to ₹34.48 lakh crore, lowest since November 2023
- Traders are closing positions earlier, reducing arbitrage and hedging activity near close
LUMIC INSIGHT
CAS volatility a big challenge for derivative traders
Economic Times·

Lumic
4 days ago
Nifty
Nifty Gainers & Losers 31st August: RBI Support Meets MSCI Rebalancing
- Pharma stocks led gains as a steadier rupee can help lower costs for imported inputs
- Sun Pharma gained 3.38%, leading Nifty as currency stability supported importers
- Adani stocks fell sharply as MSCI rebalancing flows drove heavy closing-auction moves
LUMIC INSIGHT
Rupee stability can benefit pharma by easing import costs
NSE·